Nuvalent (NASDAQ:NUVL) Insider Sells $251,547.24 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 2,589 shares of Nuvalent stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $97.16, for a total value of $251,547.24. Following the completion of the sale, the insider owned 42,134 shares in the company, valued at approximately $4,093,739.44. This represents a 5.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Deborah Ann Miller also recently made the following trade(s):

• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The shares were sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total transaction of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The shares were sold at an average price of $103.16, for a total transaction of $2,248,888.00.
• On Monday, October 20th, Deborah Ann Miller sold 5,000 shares of Nuvalent stock. The stock was sold at an average price of $94.91, for a total transaction of $474,550.00.
• On Thursday, October 16th, Deborah Ann Miller sold 12,376 shares of Nuvalent stock. The shares were sold at an average price of $91.66, for a total transaction of $1,134,384.16.
• On Wednesday, October 15th, Deborah Ann Miller sold 15,624 shares of Nuvalent stock. The shares were sold at an average price of $89.98, for a total transaction of $1,405,847.52.

Nuvalent Price Performance

NUVL stock traded up $9.62 during trading on Wednesday, reaching $106.82. The company had a trading volume of 895,694 shares, compared to its average volume of 779,373. Nuvalent, Inc. has a 52 week low of $55.53 and a 52 week high of $112.88. The business has a 50 day moving average of $102.57 and a 200 day moving average of $88.78. The company has a market cap of $7.77 billion, a P/E ratio of -20.08 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter last year, the company earned ($1.28) earnings per share. Research analysts expect that Nuvalent, Inc. will post -3.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NUVL has been the subject of several recent research reports. Truist Financial set a $140.00 price objective on Nuvalent in a research report on Monday, November 24th. JPMorgan Chase & Co. lowered their price target on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Wednesday, October 8th. Canaccord Genuity Group began coverage on shares of Nuvalent in a research note on Wednesday, November 12th. They set a “buy” rating and a $126.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and issued a $125.00 price target (up from $120.00) on shares of Nuvalent in a research report on Monday, November 17th. Fifteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $138.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in Nuvalent in the 3rd quarter worth approximately $1,297,000. Cantor Fitzgerald L. P. bought a new position in Nuvalent in the 3rd quarter valued at approximately $1,946,000. CIBC Bancorp USA Inc. bought a new position in Nuvalent in the 3rd quarter valued at approximately $396,000. Finally, Woodline Partners LP boosted its stake in Nuvalent by 18.3% during the 3rd quarter. Woodline Partners LP now owns 1,069,520 shares of the company’s stock valued at $92,492,000 after purchasing an additional 165,288 shares during the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

Nuvalent News Summary

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.